

REFERENCES

REFERENCES

- Abdel-Aziz, M.T.; Aly, H.M.; Saul, S.F. and Tadros, K. (1981):*
Report of fluorimetric method for determination of catecholamines in tissue. J. Egyptian Medical Association accepted for publication, 12-8.
- Aghajanian, G.K.; Sprouse, J.S.; Sheldon, D.; Abd Rasmussen, K. (1990):*
Electrophysiology of central serotonin system receptor subtypes and transducer mechanisms. Ann. New York Acad. Sci., 600, 93-103.
- Aguilar-Bryan, L.; Nelson, D.A.; Vu, Q.A.; Humphrey, M.B.; Boyed, A.E. III (1990):*
Photoaffinity labeling and partial purification of the B-cell sulfonylurea receptor using a novel biologically active glyburide analog. J. Biol. Chem., 265: 8218-24.
- Alfred, E.S.; Melanie, L.S.; David, L.P.; Robert, A.S. and Ian, M.B. (1983):*
Modification of chemically induced Diabetes in Rats by Vitamin E. J. Clin. Invest., 71: 1282-1288.
- Ali, H.M.; Nasra, A.; Shehab, M.M.; Osman, E.A. and Mansour, M.E. (1991):*
Effect of propranolol and chlorpromazine on the content of neurotransmitters in schizophrenic rat brain. Presented at Egypt. Soc. Pharmacol. Exp. Ther. Conference in Cairo, April, 1991.
- Amoroso, S.H.; Scchnid-Antomarchi, M.; Fosset, M.; Lazdunski (1990):*
Glucose antidiabetic sulfonylureas and neurotransmitter release. Role of ATP-sensitive K-channels. Science, 247: 852-844.
- Anon, (1996):*
Glimepiride for NIDDM Med. Lett. Drug Ther. May, 24: 38: 47-48.

- Anton, A.H. and Sayer, L. (1964):*
The distribution of dopamine and dopa in various animals and method for their determination. *J. Pharmacol. Exp. Therap.*, 145: 326-331.
- Ashcroft (1996):*
Mechanisms of the glycemic effects of sulfonylureas. *Horm. Metab. Res.*, 28 (1996), 456-463.
- Ashcroft, F.M. (1988):*
Adenosine 5' triphosphate-sensitive potassium channels. *Ann. Rev. Neurosci.*, 11: 97-118.
- Ashcroft, F.M.; Ashcroft, S.J.H. (1990):*
Properties and function of ATP sensitive K-channels. *Cell Sig.*, 2: 197-214.
- Auerbach, S. and Lipton (1985):*
Regulation of serotonin release from the rat hippocampus in vivo. Effects of alteration in the level of depolarization and rate of serotonin metabolism. *J. Neuro-Chemist.*, 44: 116-20.
- Ayres, S.Jr. (1984):*
Vitamin E: an effective therapeutic agent in dermatology. In: *Controversies in dermatology* ed. by: Evin Epstein, W.B. Saunders Company, 379: 385.
- Ayres, S.Jr. and Mihan, R. (1978):*
Porphyria cutanea tarda: Response to Vitamin E, a review and two case reports. *Cutis*, 22: 50.
- Badian, M. (1994):*
Absolute bioavailability of glimepiride (Amaryl®) after oral administration. *Drug Metab. Drug Interact.*, 11: 331-339.
- Badian, M.; Korn, A.; Lehr, K.H.; Malerczk, V. and Waldhausl, W. (1996):*
Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. *Drug Metabol. Drug Inter.* Oct., 13 (1): 69-85.

- Bakry, A. and Abdel-Tawab, S. (1979):**
Effect of lithium carbonate on brain of transmitters.. pH.
Thesis. Ain Shams University faculty of Medicine.
- Ballangi-Pordany, G.; Nemeth, M.; Aranyi, Z.; Kekesi, E.; Koltai, M.Z.; Pogatsn, G. (1992):**
Effect of glimepiride on the electrical activity of isolated rabbit heart muscle. *Arznam-Forsch/ Drug Res.*, 42: 111-113.
- Balant, L. (1981):**
Clinical pharmacokinetic of sulfonylurea hypoglycemic drugs.
Clin. Pharmacokin., 6: 215-241.
- Barham, D.; Trinder, P. (1972):**
Enzymatic calorimetric test of glucose. *Analyst*, 97: 142.
- Bartels, H. (1971):**
Mod, Method of Baters. *Clin. Chim. Acta.*, 32: 81.
- Batman, P.A.; Schever, P.J. (1985):**
Diabetic hepatitis preceeding the onset of glucose intolerance.
Histopathology, 9: 237.
- Billman, G.E.; Avendano, C.E.; Halliwill, J.R.; Burroughs, J.M. (1993):**
The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs.
J. Cardiovasc. Pharmacol., 21: 197-204.
- Bitar, M.; Koulu, M.; Rupopurt, S.I. and Linnoila, M.J. (1986):**
Diabetes-induced alterations in brain monoamine metabolism in rat, *pharmacol. Exp. Ther.*, 236: 432-437.
- Bloom, F.E. (1991):**
Drugs acting on the C.N.S. In Goodman and Gilman's the pharmacological basis of therapeutics 7th edition, Gilamn G.A., Goodman S.L.; Rall, W.T. and Murad, F. (eds.), Macmillan Publishing Co. (New York), PP. 27.
- Bowery, N.G.; Hill, D.R. and Hudson, A.I. (1983):**
Characteristics of GABA receptor binding sites on rat male brain synaptic membranes. *Br. J. Pharmac.*, 78: 191-206.

- Boyd, A.E.; Aquilur-Bryan, L.; Bryan, J. (1991):*
Sulfonylurea signal transduction.
Recent Prog. Horm. Res., 47: 299-317.
- Butturini, (1950):*
Therapy, critical study and pathogenic interpretation of vitamin
E. Giorn. Clin. Med. Fasc., 31: 1-69.
- Castano, A.; Ayala, A.; Rodriguez-Gomez, J.A.; Herrera, A.J.; Cuno,
J.; Machado, A. (1997):*
Low selenium diet increases the dopamine turnover in
prefrontal cortex of the rat. Neurochemistry International, Jun.
30 (6): 549-55.
- Chandrashekar, V.; Stequer, R.W.; Bartbe, A.; Fadden, C.T. and
Kienast, S.G. (1991):*
Influence of diabetes on the gonadotropin response to the
negative feedback effect of testosterone and hypothalamic
neurotransmitter turnover in adult male rats.
Neuroendocrinology, Jul., 54 (1): 30-5.
- Chase, T.N. and Walters, J. (1976):*
In GABA in nervous system function, ed Roberts E. Chase
T.N. and Tower D.B., New York, Raven Press, PP. 93.
- Chu, P.G.; Lin, M.T.; Shian, L.R. and Leu, S.Y. (1986):*
Alterations in physiologic functions and brain monoamine
content in streptozotocin diabetic rats, Diabetes, 34: 481-485.
- Cohwell, J.A. (1990):*
Platelet function and platelet plasma interactions in
atherosclerosis and diabetes mellitus: In Rifkin H and Porte D
Jr ed. Diabetes Mellitus, Theory and Pediatric; 4th ed. Elsevier
Science Publishing Co. Inc., 249-256.
- Consden, R.; Gorden, A.H. and Martin, A.J.P. (1944):*
Biochem. J., 41: 224-232.
- Cooper, J.R.; Bloom, F.E. and Roth, R.H. (1982):*
The biochemical basis of neuropharmacology 4th edition.
Oxford University Press. New York, PP. 213.

- Craven, P.A.; Derubertis, F.R.; Kugan, V.E.; Melhem, M.; Studer, R.K. (1997):*
Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J. Am. Soc. Nephrol. Sep., 8 (9): 1405-14.
- Creutzfeldt, W.; Frerichs, H. and Sickinger, K. (1970):*
Liver disease in diabetes progress in liver disease in Zakim Boyer a text book of liver disease edited by David Zakim M.D., Thomas, D.; Boyer, M.D. (1996): S 371-407.
- Dagleish, C.E.; Toh, C.C. and Work, T.S. (1953):*
J. Physiol., 120: 298.
- Darpy, W.J.; Feguson, M.E.; Fumar, R.H.; Lemley, J.M.; Ball, C.T. and Meneely, G.R. (1949):*
Plasma tocopherols in health and disease. Ann. N.Y. Acad. Sci., 52: 328-33. (Quoted from the American Journal of Clin-Nutr., 1973, 26: 136-143).
- Dean, P.M.; Mathews, E.K. (1968):*
Electrical activity in pancreatic islet cells. Nature, 219: 389-390.
- Defronzo, R.A.; Gunnarsson, R.; Bjorkman, O.; Olson, M.; Wahren, J. (1985):*
Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent (Type II) diabetes mellitus. J. Clin. Invest., 76: 149-155.
- DeWeille, J.R.; Lazdunski, M. (1989):*
Regulation of ATP-sensitive K^+ channels by In: Narahashi T. (ed.) Ion Channels. New York, 2: 205-222.
- DiMicco, J.A. and Gale, K. (1979):*
GABA receptor control of parasympathetic outflow to heart: characterization of brain stem localization. Science, 204: 1106-1108.
- Dinning, J.S. (1955):*
The nature of the creatinuria of nutritional muscular dystrophy in the rat. J. Nutr., 55: 209-215.

- Draeger, E. (1995):*
Glimepiride: clinical profile of glimepiride. *Diab. Res. Clin. Pract.* 28 (Suppl): S139-S146.
- Douillet, C.; Bost, M.; Accominotti, M.; Borson-Chazot, F.; Ciavatti, M. (1998):*
Effects of selenium and vitamin E supplements on tissue lipids, peroxides and fatty acid distribution in experimental diabetes. *Lipids*, April, 33 (4): 393-9.
- During, M.J.; Leone, P.; Davis, K.E.; Kerr, D.; Sherwin, R.S. (1995):*
Glucose modulates rat substantia nigra GAB release in vivo via ATP-sensitive potassium channels. *J.Clin. Invest.*, 2403-2408.
- Edwards, G.; and Weston, A.H. (1995):*
The role of potassium channels in excitable cells. *Diab. Res. Clin. Pract.*, 28: 557-566.
- Evans, H.M. and Emerson, O.H. (1936):*
Vitamin E. In: *Modern nutrition in health and disease dietotherapy*, ed. by: Goodhart, R.S.; and M.E. Shils. Lea and Febiger. Philadelphia, 5th edition, 175-185.
- Evans, H.M. and Bishop, K.S. (1922):*
On the relationship between fertility and nutrition. II The ovulation rhythm in the rat on inadequate nutritional regimes. *J. Metab. Res.*, 1: 319-365.
- Fallon, J.H. and Loughlin, S.E. (1985):*
In the rat nervous system. G. Paxinos Ed. (Academic Press, San Diego) Vol. 1: 353-374.
- Fayol, C.; Fillion, M.P. and Borone, P. (1988):*
5HT stimulates two distinct adenylate cyclase activities in rat brain, high affinity activation is related to a 5HT (1B) and 5HT (1C). *Fundam. Clin. Pharmacol.*, 2, 3:195-214.
- Feldman, J.M.; Lebovitz, H.E. (1971):*
Endocrine and metabolic effects of glibenclamide: evidence for an extrapancreatic mechanism of action. *Diabetes*, 20: 745-755.

Feldman, R.S. and Quienzer, S. (1984):

Fundamentals of neuropsychopharmacology Sunauer
Associates, Inc., Sunderland Massachusetts PP. 32-105.

Fernholtz, E. (1938):

On the constitution of alpha-tocopherol. J. Am. Chem. Soc., 60:
700-705.

*Ferrannini, E.; Lanfranchi, A.; Rohner-Jeanrenaud, F.; Manfredini,
G.; Van-de-Werve, G. (1990):*

Influence of long-term diabetes on liver glycogen metabolism
in the rat. Metabolism., 1990 Oct., 39 (10): 1082-8.

*Fushimi, H.; Inaue, T.; Kishino, B.; Nishikawa, M.; Tochino, Y.;
Funakawa, S.; Yamatodani, A. and Wada, H. (1984):*

Abnormalities in plasma catecholamine accumulation in
streptozotocin diabetic rats: a possible role for diabetic
neuropathy, life Sci., 35: 1077-1081.

Fux, K. and Ungerstedt, U. (1970):

Histochemical, biochemical and functional studies on central
monoamine neurons after acute and chronic amphetamine
administration in amphetamines and related compounds
proceeding of Mario Negri institute for Pharmacological
research, Milan, Italy, Edited by Costa E. and Garattini S.
Raven press New York, PP. 257.

Geisen, K. (1988):

Special pharmacology of the new sulfonylurea Glimpeiride.
Arzneimittelforschung/ Drug Research, 38: 1120-1130.

Gerich, J.E. (1985):

Sulfonylureas in the treatment of diabetes mellitus. May Clin.
Proc. Jul., 60 (7): 439-43.

Gray, J.A.; Metz, A.; Goodwin, G.M. and Green, A.R. (1986):

The effect of the GABA mimetic drugs progaldide and baclofen
on the noradrenaline. Neuropharmacology, 25: 711-716.

Grebb, J.A. and Reus, V.I. (1984):

Neurobehavioral chemistry and physiology in Review of
General psychiatry, Chapter 11, Middle east edition, Ed.
Goldman H.A., Lange Medical publications, PP. 125.

- Green, J. (1970):*
In "The Fat-Soluble Vitamins" (H.F. Deluca and J.W. Suttie, eds), PP. 293-305 Univ. of Wisconsin Press, Madison.
- Green, J. (1972):*
Vitamin E and the biological antioxidant theory. Am. N.Y. Acad. Sci., 203: 29-44.
- Hansen, J.M.; Christensen, L.K. (1977):*
Drug in reactions with oral sulfonylurea hypoglycemic agents. Drugs, 13: 24-34.
- Harris, M.I.; Hadden, W.C.; Knowler, W.C. and bennett, P.H. (1985):*
International criteria for diagnosis of diabetes and impaired glucose tolerance. Diabetes Care (8): 562-567.
- Henquin, J.C. (1980):*
Tolbutamide stimulation and inhibition of insulin release: studies of the underlying mechanisms in rat islets. Diabetologia, 18: 151-160.
- Heslop, K.E.; Goss-Sampson, M.A.; Muller, D.P.; Gurzon, G. (1996):*
Serotonin metabolism and release in frontal cortex of rats on a vitamin E-deficient diet. Journal of Neurochemistry 66 (2): 860-4.
- Hosker, J.P.; Burnett, M.A.; Davis, E.G.; Harris, E.A.; Turner, R. (1985):*
Sulfonylurea therapy doubles B-cell response to glucose in type II diabetic patients. Diabetologia, 28: 8909-8914.
- Huupponen, R. (1987):*
Adverse cardiovascular effects of sulfonylurea drugs-clinical significance. Med. Toxicol., 2 (3): 190-209.
- Inagaki, N.; Gono, T.; Clement, J.P.; Namba, W.N.; Inazawa, J.; Gonzalez, G.; Aguilar-Bryan, L.; Seino, S.; Bryan, J. (1995):*
Reconstitution of K_{ATP} : an inward rectifier subunit plus the sulfonylurea receptor. Science, 270: 1166-1169.

Iversen, L.L. (1967):

Regional study of catecholamines in the rat brain. The distribution of (H^3) norepinephrine, (H^3) dopamine, (H^3) dopa in rat brain. *J. Neurochem*, 13: 655-669.

Johnson, P.J. (1991):

The effect of endocrine disease on liver function in Oxford text book of clinical hepatology volume II edited by Neil McIntyre, Jean-Pierre, Benhamou, Johannes, Birchen, Mario Rizzetto and Juan Rodes, S 1194-S 1196.

Joseph, J.A.; Erat, S.; Denisova, N.; Villaobos-Molina, R. (1998):

Receptor-and age-selective effects of dopamine oxidation on receptor-G protein interactions in the striatum. *Free Radical Biology & Medicine*, 24 (5): 827-34.

Karam, J.H. (1983):

Pancreatic hormones and antidiabetic drugs. *Basic and Clinical Pharmacology*, Katzung, B.G., PP. 464-469.

Karrer, P.; Frintzsche, H.; Ringor, B.H.; Salomon, H. (1938):

Alpha tocopherol. *Helv. Chem. Acta.*, 21: 520-525.

Kolta, M.G.; Soliman, F.A. and Williams, B.B. (1986):

Role of 5-hydroxytryptamine in the regulation of brain neuropeptides in normal and diabetic rat, *Horm. Res.*, 23: 112-121.

Kolterman, Q.G.; Gray, R.S.; Shapiro, G.; Griffin, J.A.; Olefsky, J.M. (1994):

The acute and chronic effect of sulfonylurea therapy in type II diabetic patients. *Diabetes*, 33: 346-345.

Kopin, I.J. (1985):

Catecholamine metabolism: Basic aspects and clinical significance. *Pharmacol. Rev.*, 37, 4: 333-51.

Kawloru, R.; Kern, t.S.; Engerman, R.I. (1994):

Abnroamlities of retinal metabolism in diabetes or galacosemia. II Comparison of gamma-glutamyl transpeptidase in retina and cerebral cortex and effects of antioxidant therapy. *Curr Eye. Res. Dec.*, 13 (12): 891-6.

- Kramer, W.; Muller, G.; Geisen, K. (1996):*
Characterization of the molecular mode of action of the sulfonylurea glimepiride, at B-cells. *Horm. Metab. Res.*, 28: 464-468.
- Kramer, W.; Muller, G.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Hartz, D.; Summ, H.D. (1994):*
Differential interaction of glimepiride and glibenclamide with the B-cell sulfonylurea receptor, II photoaffinity labelling of a 65-Kda protein by [3 H] glimepiride. *Biochem. Biophys. Acta.*, 1191: 278-290.
- Kramer, W.; Muller, G.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Hartz, D.; Summ, H.D. (1995):*
The molecular interaction of sulfonylureas with B-cell ATP-sensitive K $^+$ channels. *Diab. Res. Clin. Pract.*, 28: 567-580.
- Krishnamurthy, S. and Bieri, J.G. (1963):*
J. Lipid Res., 4: 330.
- Kurahashi, M.; Masui, H.; Yoshimoto, S.; Wakabayashi, I. And Sakumoto, K. (1993):*
Effect of diethyldithio carbanate on diabetogenic action of alloxan in rats.
Diabetes, Res. Clin. Pract., 1993 Jan., 19 (1): 39-47.
- Kwok, R.P.S.; Walls, E.K. and Juorio, A.V. (1985):*
The concentration of dopamine, 5-hydroxytryptamine and some of their acid metabolites in the brain of genetically diabetic rat. *Neurochem. R.*, 10: 611-616.
- Lackovic, Z.; Salkvic, M. (1990):*
Streptozotocin and alloxan produce alterations in rat brain monoamines in dependently of pancreatic beta cells destruction.
Life Sci. 46 (1): 49-54.
- Landry, D.W.; Oliver, J.A. (1992):*
The ATP-sensitive K $^+$ channel modulates hypotension in endotoxemia and hypoxic lactic acidosis in dogs. *J. Clin. Invest.*, 89: 2071-2074.

- Langer, S.Z. (1981):**
Presynaptic regulation of the release of catecholamines. *J. Pharmacol. Exp. Ther.*, 32: 4, 337-55.
- Langtry, H.D.; Balfour, J.A. (1998):**
Glimepiride. A review of its use in the management of type 2 diabetes mellitus. *Drugs*, Apr., 55 (4): 563-84.
- Lazdunski, M. (1996):**
Ion channel effects of antidiabetic sulfonylureas. *Horm. Metab. Res.*, 28: 488-495.
- Lebovitz, H.E. and Passmantier, R. (1990):**
Combination insulin-sulfonylurea therapy. *Diabetes Care*: 13: 667-675.
- Lee, C.S.; Mauer, S.M.; Brown, D.M. et al. (1974):**
Renal transplantation in D.M. in rats. *J. Exp. Med.*, 139: 793-800.
- Lefkowitz, J.R.; Hoffman, B.B. and Taylor, P. (1991):**
Neurohumoral transmission. In Goodman and Gilman, S the pharmacological basis of therapeutics, 8th edition, chapter 5, Ed. Alfred Goodman Gilman, Rall T.W., Nies A.S., and Taylor P. Published by Pergamon Press, PP. 99.
- Lehr, K.H. and Damm, P. (1990):**
Simultaneous determination of the sulfonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. *J. Chromatogr. Apr.*, 6, 526 (2): 497-505.
- Lewis, J.S.; Pian, A.K.; Baer, M.T.; Acosta, P.B.; Emerson, G.A. (1973):**
Effect of long-term ingestion of polyunsaturated fat, age, plasma cholesterol, diabetes mellitus, and supplemental tocopherol upon plasma tocopherol. *Am. J. Clin. Nutr.*, 26: 136-43.
- Levein, T.; Bakar, D.E. (1996):**
Reviews of glimepiride and anastrozole. *Hosp. Pharm.*, Oct. (31): 1297-1310.

- Lobely, G.E.; Perry, S.V.; Stone, D. (1971):*
Structural changes in myosin induced by vitamin E dystrophy.
Nature, 331, 317-8.
- Lovell, R.A. and Elliot, K.A.C. (1963):*
Br. Med. Bull., 29-2.
- Lozovsky, D.; Saller, C. and Kopin, I. (1981):*
Dopamine receptor binding is increased in diabetic rats. Science,
214: 1031-1033.
- Lucy, J.A. (1972):*
Functional and structural aspects of biological membranes. A
suggested structural role for vitamin E in the control of
membrane permeability and stability. Ann. N. Y. Acad. Sci.,
203: 4-11.
- Malerczyk, V. (1994):*
Dose linearity assessment of glimepiride (Amaryl®) tablets in
healthy volunteers. Drug Metab. Drug interact, 11: 341-357.
- Mallerczyk, V.; Badian, M.; Korn, A.; Lehr, K.H.; Waldhausli, W.
(1994):*
Dose linearity assessment of glimepiride (Amaryl®) tablets in
healthy volunteers. Drug Metab. Drug Interact., 77: 341-357.
- Mansour, M.E. (1997):*
Anticonvulsant effect of phenobarbitone. A possible
mechanism of action. Benha Med. J. Vol., 14, No. 1, Jan, 1997.
- Marshall, S.; Garvey, W.T.; Traxinger, R.R. (1991):*
New insights into the metabolic regulation of insulin action and
insulin resistance: role of glucose and amino acids. FASEB
Journal, 5: 3031-3035.
- Martin, F.J.; Miguez, J.M.; Aldequnde, M.; Atienza, G. (1995):*
Effect of streptozotocin induced -diabetes mellitus on
serotonine measures of peripheral tissues in rats.
Life Sci., 56 (1): 51-9.
- Mason, S.T. (1984):*
Catecholamines and behaviour Ed. Mason S.T., 1st ed.,
Cambridge University press, PP. 9-17.

McCarthy, S.T.; Harris, F.; Turner, R.C. (1977):

Glucose control of basal insulin secretion in diabetes. *Diabetologia* (13): 93-97.

McIlwain, H. and Bachelard, H.S. (1985):

Biochemistry and central nervous system, 5th ed., Churchill Livingstone Edinburgh, London Melbourne and New York PP. (441).

McMasters, V.; Howard, T.; Kinsell, L.W.; Van Der Veen, J.; Olcott, H.S. (1967):

Tocopherol storage and depletion in adipose tissue and plasma of normal and diabetic human subjects. *Am. J. Clin. Nutr.*, 20: 622-6.

Merali, Z.; Ahmad, Q.; Veitch, J. (1988):

Behavioral and neurochemical profile of the spontaneously diabetic wistar BB rat.

Behav. Brain Res. Jul., 29 (1-2): 51-60.

Middlemiss, D.N. and Huston, P.H. (1990):

The 5HT (1B) receptors. *Ann. New York Acad. Sci.*, 660, 132-148.

Morita, K.; Nakanishi, A.; Murakumo, Y.; Oka, M.; Teraoka, K. (1988):

Effects of hypoglycemic sulfonylureas on catecholamine secretion and calcium uptake in cultured bovine adrenal chromaffin cells. *Biochem. Pharmacol.*, 37: 983-985.

Morita, K.; Teraoka, K.; Oka, M.; Azuma, A.M. (1990):

Effect of hypoglycemic sulfonylurea, glibenclamide, on the rate of catecholamine synthesis in cultured adrenal chromaffin cells. *Biochem. Pharmacol.*, 1990 Mar, 1; 39 (5): 976-8.

Mourre, C.; BenAri, Y.; Bernardi, H.; Fosset, M.; Lazdunsk, M. (1989):

Antidiabetic sulfonylureas: localization of the binding sites in the brain and effects on the hyperpolarization induced by anoxia in hippocampal slices. *Brain Res.*, 486: 159-164.

- Mourre, C.; Widmann, C.; Lazdunski, M. (1990):*
Sulfonylurea binding sites associated with ATP-regulated K⁺ in the central nervous system: autoradiographic analysis of their distribution and of their localization in mutant mice cerebellum. *Brain Res.*, 519: 29-34.
- Muller, G.; Geisen, K. (1995):*
Extrapaneatic effects of sulfonylureas a comparison between glimepiride and conventional sulfonylureas. *Diabetes Res. Clin. Pract.*, 2: 5115-5137.
- Muller, G.; Geisen, K. (1996):*
Characerization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. *Horm. Metab. Res.*, 28: 469-487.
- Muller, R.A.; Thoein, H. and Axelrod, J. (1969):*
Increase in tyrosine hydroxylase activity after reserpine administration. *J. Pharmacol., Exp. Ther.*, 169, 1: 74-79.
- Nason, A. and Lehman, I.R. (1965):*
The role of lipids in electron transport. II Lipid cofactor replaceable tocopherol for the enzymatic reduction of cytochrome C.G. *Biol. Chem.*, 222: 511-530.
- Neal, M.J. (1987):*
Drugs used in psychosis-neuroleptics in medical pharmacology at a glance 1st edition, editors, Neal M.J., Blackwell Scientific Publications., Oxford, London, PP. 56.
- Noma, A.; Shibasaki, T. (1985):*
Membrane current through adenosine triphosphate-regulated potassium channels in guinea-pig ventricular cells. *J. Physiol.*, 363: 463-480.
- Olsen, R.E. (1977):*
Vitamin E and its relation to heart disease. *Circulation*, 48: 179-184.
- Ozaki, Y.; Yatomi, Y.; Kume, S. (1992):*
Effects of oral hypoglycemic agents on platelet functions. *Biochem. Pharmacol.*, 44: 687-691.

Papaccin, G.; Baccaro, G.C.; Frascatores, S.; Sellitti, S.; Pisanti, F.A. (1995):

The vitamin-E derivative N-83836-E in the low-dose streptozotocin treated mouse: effects on diabetes development. Diabetes, Res. Clin. Pract. Dec., 30 (3): 163-71.

Parfitt, K.D.; Hoffer, B.J. and Bickfordwimer, P.C. (1990):

Potentiation of gamma-aminobutyric acid-mediated inhibition by isoproterenol in the cerebellar cortex; Receptor specificity. Neuropharmacol., 29/10 (909-916).

Passmore, R. and Robson, J.S. (1980):

Drugs acting on C.N.S., In A Companion to medical studies, chapter 6, volume 2, 2nd Ed., Passmore, R. and Robson J.S. (editors). Blackwell Scientific Publications, Boston, PP. 25.

Pletcher, A. (1973):

In Frontiers in catecholamine Research (ed. Usdin E., and Snyder S.H.) Oxford, Pergamon, P. 27.

Rabkin, R.; Simon, N.M.; Steiner, S.; Colwell, J.A. (1970):

Effect of renal disease on renal uptake and excretion of insulin in man. N. Engl. J. Med., 282: 182-187.

Raiteri, M. and Bonanno, G. (1987):

Coexistence of carriers for dopamine and GABA uptake on a same nerve terminal in the rat brain. Br. J. Pharmac., 91: 237-243.

Retiman and Franked, (1957):

A calorimetric method for determination of serum glutamic oxaloacetic acid and glutamic pyruvic transaminase. Ann. Clin. Pathol. J., 28: 156.

Rius, F.; Pizarro, E.; Castells, I.; Sulinas, I.; Sanmarti, A.; Romero, R. (1996):

Renal functional changes in hypertensive patients with non-insulin dependent diabetes mellitus. Kidney- Int. Suppl., 1996 Jun., 55: 588-90.

Roberts, E. and Frankle, S. (1950):

Am. J. of Physiology, 55-63.

- Robertson, D.A.; Home, P.D. (1993):*
Problems and pitfalls of sulfonylurea therapy in older patients. *Drugs Aging*, 3: 510-524.
- Roels, O.A. (1967):*
Present knowledge of vitamin E. *Nutr. Rev.*, 25: 33-37.
- Rosenkranz, B. (1996):*
Pharmacokinetic basis for the safety of glimepiride in risk groups for NIDDM patients. *Horm. Metab. Res.*, 28: 434-439.
- Rosenstock, J.; Samnols, E.; Muchmore, D.B.; Schneider, J. (1996):*
Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride study group. *Diabetes, Care.*, Nov., 19 (11): 1194-9.
- Sakura, H.; Ammalu, C.; Smith, P.A.; Gribble, F.M.; Aschruft, F.M. (1995):*
Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel expressed in pancreatic B-cells, brain, heart and skeletal muscle. *FEBS Lett.*, 377: 338-344.
- Saller, C. (1984):*
Dopaminergic activity is reduced in diabetic rats, *Neurosci. Lett.*, 49: 301-306.
- Sandrini, M.; Vitale, G.; Vergoni, A.V.; Otlani, A.; Bertolini, A. (1997):*
Streptozotocin-induced diabetes provokes changes in serotonin concentration on 5-HT(1A) and 5-HT2 receptors in the rat brain. *Life, Sci.*, 60 (16): 1393-7.
- Sauer, L.A.; Dauchy, R.T. (1987):*
Stimulation of tumor growth in adult rats in vivo during acute streptozotocin-induced diabetes. *Cancer, Res. Apr.*, I, 47(7): 1756-1761.
- Schemer, (1967):*
The blood morphology of laboratory, 3rd ed., PP. 43 Davis F.A. Company, Philadelphia.

- Schmid-Antonmarchi, H.; Amoroso, S.; Fosset, M.; Lazdunski, M. (1990):*
K⁺ channel openers activate brain sulfonylurea sensitive K⁺ channels and block neurosecretion. Proc. Natl. Acad. Sci., U.S.A., May., 87 (9): 3489-92.
- Schwarz, K.; Baumgartner, W. (1970):*
In the fat soluble vitamins. (ed) by Deluca HF and Suttie, J.W.; Madison, Wisconsin, PP. (317).
- Seeman, P. (1981):*
Brain dopamine receptors. Pharmacol. Rev., 32, 3: 230-263.
- Shepherd, M.; Loder, J. and Rodinight, I. (1968):*
Clinical psychopharmacology. The English University Press Ltd. Lon. PP., 214.
- Silberberg, S.D.; Van Breemen, C. (1990):*
An ATP, calcium and voltage sensitive potassium channel in porcine coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun., 172: 517-522.
- Simpson, L.L. (1976):*
Amphetamine and related stimulants. In. Drug treatment of Mental disorders, chapter II, Edited by Simpson L.L., Raven Press, New York, PP. 15.
- Skglund, G.; Gross, R.A.; Bertrand, G.R.; Ahren, B.; Loubatieres-Mariani, M.M. (1991):*
Comparison of effects of neuropeptide Y and norepinephrin on insulin secretion and vascular resistance in perfused rat pancreas. Diabetes, Jun, 40 (60): 660-5.
- Sonsalla, K.P.; Gibb, W.J. and Hanson, R.G. (1986):*
Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monamine system.
- Sourks, T. and Murphy, G.F. (1965):*
Determination of catecholamines and catecholaminoacids. In: Methods in medical research (Chicago). The year book publishers, Inc. Vol., 9, PP. 147-152.

- Standen, N.B.; Quayle, J.M.; Davis, N.W.; Brayden, J.E.; Huang, Y.; Nelson, M.T. (1989):*
Hyperpolarizing vasodilators activate ATP-sensitive potassium channels in arterial smooth muscle cells. *Science*, 245: 177-180.
- Sturgess, N.C.; Ashford, M.L.J.; Cook, D.L.; Hales, C.N. (1985):*
The sulfonylurea receptor may be an ATP-sensitive potassium channel. *Lancet*, 474-475.
- Sumiyoshi, T.; Ichikawa, J. and Meltzer, H.Y. (1997):*
The effect of streptozotocin induced diabetes on dopamine 2, serotonin 1A and serotonin 2A receptors in the rat brain. *Neuropsychopharmacology*, Mar., 16 (3): 183-190.
- Swonger, M.F. and Constantine, L.L. (1976):*
Serotonin and GABA, Drug and therapy. Little Brown Co. Boston, PP. 76-80.
- Tappel, A.L. (1970):*
In: The fat soluble vitamins, (H.F. Deluca and J.W. Suttie, eds.), PP. 369-374. Univ. of Wisconsin Press, Madison.
- Thorre, K.; Chaoulhoff, F.; Sarre, S.; Meeusen, R.; Ebinger, G.; Michotte, Y. (1997):*
Differential effects of restraint stress on hippocampal 5-HT metabolism and extracellular levels of 5-HT in streptozotocin-diabetic rats.
Brain Res. Oct., 24: 772 (1-2): 209-16.
- Trulson, M. and Himmel, C. (1985):*
Decreased brain dopamine synthesis rate and increased (3H) spiroperidol binding in streptozotocin diabetic rats, *J. Neurochem.*, 40: 1456-1459.
- Tsumura, K.; Draeger, E. (1995):*
Clinical evaluation of glimepiride (Hoe 490) in NIDDM including a double blind comparative study versus gliclazide. *Diabetes Res. Clin. Pract.*, 28: S147-S149.
- Twarog, B.M. and Page, J.H. (1953):*
Serotonine content of some mammilian tissues and urine and methods for its determination. *Am. J. of Physiol.*, 175: 157.

- Vaccaro, O.; Rivellese, A.; Riccard, G.; Capaldo, Tutino, L.; Annuzzi, G. and Macini, M. (1984):*
Impaired glucose and risk factors for atherosclerosis. *Atherosclerosis*. (4): 592-597.
- Vagner, E.A.; Khlebnikov, V.V.; Terekhina, N.A.; Palatova, L.F. (1997):*
Antioxidants in the treatment of cholelithiasis patients vestn. *Khir. Im. I.; Grek*, 1997; 156 (1): 36-39.
- Van Kammen, L. (1977):*
Aminobutyric acid and the dopamine hypothesis of schizophrenia. *Am. J. Psych.*, 134, 2: 138-143.
- Voss, C.; Brachmann, K.; Hartman, K. (1988):*
Effect of streptozotocin on transaminase, creatinine and urea in serum of rats. *Exp. Clin. Endocrinol. Sep.*, 92(1): 37-42.
- Waldhausl, P. (1996):*
Role of sulfonylurea in Non-insulin dependent diabetes mellitus. *Horm. Metab. Res.*, (28): 517-521.
- Webster, G.J.; Petch, E.W.; Cowen, T. (1990):*
Streptozotocin-induced diabetes in rats causes neuronal deficits in tyrosine hydroxylase and 5-hydroxy tryptamine specific to mesentric perivascular sympathetic nerves and without loss of nerve fibers. *Exp. Neurol. Jul.* 113 (1): 53-62.
- Wei, Q.; Yeung, M.; Jurma, O.P.; Andersen, J.K. (1996):*
Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. *Journal of Neuroscience Research*, 46 (6): 666-73.
- Weissback, H. (1965):*
Determination of serotonin spectrofluorophotometric methods in medical research. *Chicago year book Inc. Publisher Inc.* Volume, 9, P. 178.
- Wild, A.A.M.G.; Aksens (1995):*
Myocardial potassium and cell depolarization in ischemia and hypoxia. *Cardiovasc. Res.*, 29: 1-15.

- Wilkinson, D.G. (1981):*
Psychiatric aspects of diabetes mellitus.
Br. J. Psychiatr., 138: 1-9.
- Wood, P.L. and Altar, C.A. (1988):*
Dopamine release in vitro from nigrostriatal mesolimbic, and mesocortical neurons. Utility of 3-Methoxytyromine measurements. Pharmacol. Rev., 40,3 : 164-180.
- Yang, X.; Borg, L.A.; Siman, C.M.; Eriksson, U.J. (1998):*
Maternal antioxidant treatments prevent diabetes-induced alterations of mitochondrial morphology in rat embryos.
Anant. Rec. Jul., 251 (3): 303-15.
- Yarborough, M.; Steil, C. (1989):*
Oral hypoglycemic agents. Applications of current research.
Diabetes, Sepectrum; (2): 294-322.
- Yeh, H.H. and Woodward, D.J. (1983):*
B1 adrenergic receptors mediate noradrenergic facilitation of purkinje cell responses to GABA in cerebellum of rat.
Neuropharmacology, 22: 5, (629-639).
- Yen, G.C.; Hsieh, C.L. (1997):*
Antioxidant effects of dopamine and related compounds.
Bioscience, Biotechnology & Biochemistry, 61 (10): 1646-9.
- Young, W.S. and Kohar, M.J. (1979):*
Noradrenergic alpha 1 and alpha 2 receptors autoradiographic visualization. Eur. J. Pharmacol., 59: 317-319.